Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Biocon Ltd. Regulatory Filings 2021

Apr 12, 2021

61176_rns_2021-04-12_57950232-dc16-48a3-9d6d-630873efb0c5.pdf

Regulatory Filings

Open in viewer

Opens in your device viewer

==> picture [132 x 52] intentionally omitted <==

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com

April 12, 2021

To
The Manager,
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street,Mumbai – 400 001
To
The Manager,
National Stock Exchange of India Limited
Corporate Communication Department
Exchange Plaza, Bandra Kurla Complex
Mumbai – 400 050
Scrip Code - 532523 Scrip Symbol - Biocon

Subject: Company Statement

Dear Sir/Madam,

Please find below a Company Statement titled “Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, receives GMP compliance certificate from MHRA, UK.”

“This is to inform you that Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received a certificate of Good Manufacturing Practice (GMP) compliance from the Medicines & Healthcare products Regulatory Agency (MHRA), the United Kingdom (UK), for its manufacturing facility at Biocon Park in Bengaluru.

The certificate, which includes manufacturing and packaging of tablets and capsules in the non-potent and potent blocks of the facility, was issued based on a remote inspection in the week of 22nd March, 2021, in the wake of travel restrictions amidst Covid-19.”

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

MAYANK Digitally signed by MAYANK VERMA VERMA Date: 2021.04.12 08:21:33 +05'30' ___

Mayank Verma Company Secretary and Compliance Officer